prikaz prve stranice dokumenta Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
  Preuzmi
PDF 261 KB
Znanstveni rad - Izvorni znanstveni rad
Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
Journal of Personalized Medicine, 12 (2022), 7; 1176. https://doi.org/10.3390/jpm12071176
Čerina, Dora; Matković, Višnja; Katić, Kristina; Belac-Lovasić, Ingrid; Šeparović, Robert; Canjko, Ivana; Bajić, Žarko; Vrdoljak, Eduard

Citiranost:
,
Citirajte ovaj rad

Čerina, D., Matković, V., Katić, K., Belac Lovasić, I., Šeparović, R., Canjko, I. ... Vrdoljak, E. (2022). Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia. Journal of Personalized Medicine, 12. (7). doi: 10.3390/jpm12071176

Čerina, Dora, et al. "Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia." Journal of Personalized Medicine, vol. 12, br. 7, 2022. https://doi.org/10.3390/jpm12071176

Čerina, Dora, Višnja Matković, Kristina Katić, Ingrid Belac Lovasić, Robert Šeparović, Ivana Canjko, Žarko Bajić i Eduard Vrdoljak. "Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia." Journal of Personalized Medicine 12, br. 7 (2022). https://doi.org/10.3390/jpm12071176

Čerina, D., et al. (2022) 'Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia', Journal of Personalized Medicine, 12(7). doi: 10.3390/jpm12071176

Čerina D, Matković V, Katić K, Belac Lovasić I, Šeparović R, Canjko I, i sur.. Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia. Journal of Personalized Medicine [Internet]. 19.07.2022. [pristupljeno 03.04.2025.];12(7). doi: 10.3390/jpm12071176

D. Čerina, et al., "Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia", Journal of Personalized Medicine, vol. 12, br. 7, Srpanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:271091. [Citirano: 03.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:271091
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
AutorDora Čerina
AutorVišnja Matković
AutorKristina Katić
AutorIngrid Belac-Lovasić
AutorRobert Šeparović
AutorIvana Canjko
AutorŽarko Bajić
AutorEduard Vrdoljak
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Sažetak (engleski)
Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequencing (NGS) have enabled comprehensive genomic profiling (CGP) analysis to become more feasible for routine use in daily clinical work. Here, we present the results for the first two years of an... Više analysis of patients with advanced ovarian cancer on a national level. The aim was to establish the position of CGP in the daily clinical practice of treating ovarian cancer. We performed a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients who were newly diagnosed with locally advanced or metastatic ovarian cancer or whose initial disease had progressed from 1 January 2020 to 1 December 2021, and whose tumors underwent CGP analysis. All 86 patients (100%) analyzed with CGP had at least one genomic alteration (GA). The median LOH was 14.6 (IQR 6.8–21.7), with 35 patients (41%) having an LOH ≥ 16. We found BRCA-positive status in 22 patients (26%). Conventional testing, which detects only BRCA mutations, would have opted for therapy with PARP inhibitors in 22 (26%) of our patients. However, CGP revealed the need for PARP inhibitors in 35 patients (41%). The results identified a significantly higher number of women who would achieve a possible benefit from targeted therapy. Hence, we believe that CGP should be a backbone diagnostic tool in the management of ovarian cancer. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Personalized Medicine
Brojčani podacivol. 12, br. 7, 1176
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm12071176
URN:NBNurn:nbn:hr:184:271091
Datum objave publikacije2022-07-19
URL dokumentahttps://www.mdpi.com/2075-4426/12/7/1176
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-09-21 12:35:53
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.